Drugs / TTX-080
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04485013 | Jul 2020 → Jun 2027 expected | cancer | Tizona Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTX-080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04485013 ↗ |
| Action | Inhibit | “TTX-080 is a fully human mAb designed to block the interaction of HLA-G with its known ligands, ILT2 and ILT4 molecules.” NCT04485013 ↗ |
| Modality | Monoclonal antibody | “TTX-080 is a fully human mAb” NCT04485013 ↗ |